A detailed history of Glenmede Trust CO Na transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Glenmede Trust CO Na holds 14,981 shares of PTGX stock, worth $696,017. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,981
Previous 15,506 3.39%
Holding current value
$696,017
Previous $537,000 25.33%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$33.72 - $47.33 $17,703 - $24,848
-525 Reduced 3.39%
14,981 $673,000
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $99,996 - $141,114
4,055 Added 35.41%
15,506 $537,000
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $249,517 - $368,149
11,451 New
11,451 $331,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.28B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Glenmede Trust CO Na Portfolio

Follow Glenmede Trust CO Na and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.